1. Home
  2. KODK vs PRTA Comparison

KODK vs PRTA Comparison

Compare KODK & PRTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Eastman Kodak Company Common New

KODK

Eastman Kodak Company Common New

HOLD

Current Price

$8.86

Market Cap

705.6M

ML Signal

HOLD

Logo Prothena Corporation plc

PRTA

Prothena Corporation plc

HOLD

Current Price

$11.02

Market Cap

595.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
KODK
PRTA
Founded
1880
2012
Country
United States
Ireland
Employees
N/A
N/A
Industry
Business Services
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
705.6M
595.9M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
KODK
PRTA
Price
$8.86
$11.02
Analyst Decision
Buy
Analyst Count
0
9
Target Price
N/A
$18.86
AVG Volume (30 Days)
2.0M
621.0K
Earning Date
11-06-2025
11-06-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$1,045,000,000.00
$11,786,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$819.08
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$4.93
$4.32
52 Week High
$9.31
$17.66

Technical Indicators

Market Signals
Indicator
KODK
PRTA
Relative Strength Index (RSI) 70.42 59.50
Support Level $7.50 $10.14
Resistance Level $8.67 $11.57
Average True Range (ATR) 0.43 0.57
MACD 0.11 0.06
Stochastic Oscillator 82.12 71.70

Price Performance

Historical Comparison
KODK
PRTA

About KODK Eastman Kodak Company Common New

Eastman Kodak Co is a United States-based company. It operates through several business segments; Print, Brand, and Advanced Materials and Chemicals. The Print segment which derives the majority of revenue includes products like digital offset plate offerings and computer-to-plate imaging solutions, high-quality digital printing solutions using electrically charged toner-based technology, production press systems, consumables, inkjet components, software and services. Geographically, the company generates revenue from the United States, Canada, Europe, Middle East and Africa, Asia Pacific, and Latin America.

About PRTA Prothena Corporation plc

Prothena Corp PLC is a clinical biotechnology company that focuses on protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of devastating neurodegenerative and rare and peripheral amyloid diseases. The company's clinical pipeline of antibody-based product candidates targets a range of indications, including Amyloid Light-chain (AL) amyloidosis (NEOD001), Parkinson's disease and other related synucleinopathies (PRX002), and inflammatory diseases, including ATTR amyloidosis [Coramitug (PRX004)], Alzheimer's disease (PRX123), Neurodegeneration (PRXPRX019), and Others.

Share on Social Networks: